Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction

IMPORTANCE: Heart failure with reduced ejection fraction produces substantial morbidity, mortality, and health care costs. Dapagliflozin is the first sodium-glucose cotransporter 2 inhibitor approved for the treatment of heart failure with reduced ejection fraction. OBJECTIVE: To examine the cost-ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Isaza, Nicolas, Calvachi, Paola, Raber, Inbar, Liu, Chia-Liang, Bellows, Brandon K., Hernandez, Inmaculada, Shen, Changyu, Gavin, Michael C., Garan, A. Reshad, Kazi, Dhruv S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317009/
https://www.ncbi.nlm.nih.gov/pubmed/34313742
http://dx.doi.org/10.1001/jamanetworkopen.2021.14501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317009/
https://www.ncbi.nlm.nih.gov/pubmed/34313742
http://dx.doi.org/10.1001/jamanetworkopen.2021.14501

Ejemplares similares